by Olalekan Daramola, Diane Hatton, and Ray Field
Volume 5, Issue 2 (Summer 2006)
A number of antibody drugs are currently in clinical development and 22 antibodies (including five diagnostic antibodies) have received FDA market approval in the last decade. A number of different technologies are now being used successfully to isolate potent therapeutic antibodies with minimal immunogenicity and improved safety. These include chimerisation (mouse/human antibodies), humanisation (complementarity-determining region [CDR] grafting), transgenic mice, phage display, ribosome display, and other emerging technologies. The phage and ribosome display technologies used at Cambridge Antibody Technology (CAT) are based on the physical linkage of gene to gene product which enables the recovery and enrichment of genetic material encoding the selected antibody…
Citation:
Daramola O, Hatton D, Field R. Meeting the Challenges of IgG Expression: From Antibody Libraries to Clinical Supply. BioProcess J, 2006; 5(2): 21-25. https://doi.org/10.12665/J52.Daramola